Evidence map›Paper›PMID 21248136›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2011

Mitochondrial reactive oxygen species are activated by mGluR5 through IP3 and activate ERK and PKA to increase excitability of amygdala neurons and pain behavior.

Zhen Li, Guangchen Ji, Volker Neugebauer

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Bioactive Compounds for Fibromyalgia-like Symptoms: A Narrative Review and Future Perspectives.International journal of environmental research and public health · 2022
    Review
  14. Article
  15. Article
  16. Article
  17. Blocking glutamate mGluBritish journal of pharmacology · 2021
    Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Zhen LiDepartment of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, Texas 77555-1069, USA.
Guangchen Ji
Volker Neugebauer
The University of Texas Medical Branch at Galveston · US

Funding

VISCERAL PAINP01NS011255 · NINDS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI CHUNG, JIN M · 1985 to 2012
$13.6M
PAIN, NOCICEPTION, AND THE AMYGDALAR01NS038261 · NINDS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI Volker Neugebauer, Igor Ponomarev · 1999 to 2026
$8.7M
NINDS NIH HHS NS-11255NINDS NIH HHS NS-38261NINDS NIH HHS P01 NS011255NINDS NIH HHS R01 NS038261
6 · The paper itself

Abstract

Reactive oxygen species (ROS) such as superoxide are emerging as important signaling molecules in physiological plasticity but also in peripheral and spinal cord pain pathology. Underlying mechanisms and pain-related ROS signaling in the brain remain to be determined. Neuroplasticity in the amygdala plays a key role in emotional-affective pain responses and depends on group I metabotropic glutamate receptors (mGluRs) and protein kinases. Using patch-clamp, live-cell imaging, and behavioral assays, we tested the hypothesis that mitochondrial ROS links group I mGluRs to protein kinase activation to increase neuronal excitability and pain behavior. Agonists for mGluR1/5 (DHPG) or mGluR5 (CHPG) increased neuronal excitability of neurons in the laterocapsular division of the central nucleus of the amygdala (CeLC). DHPG effects were inhibited by an mGluR5 antagonist (MTEP), IP(3) receptor blocker (xestospongin C), or ROS scavengers (PBN, tempol), but not by an mGluR1 antagonist (LY367385) or NO synthase inhibitor (l-NAME). Tempol inhibited the effects of IP(3) but not those of a PKC activator, indicating that ROS activation was IP(3) mediated. Live-cell imaging in CeLC-containing brain slices directly showed DHPG-induced and synaptically evoked mitochondrial superoxide production. DHPG also increased pain-related vocalizations and spinal reflexes through a mechanism that required mGluR5, IP(3), and ROS. Combined application of inhibitors of ERK (U0126) and PKA (KT5720) was necessary to block completely the excitatory effects of a ROS donor (tBOOH). A PKC inhibitor (GF109203X) had no effect. Antagonists and inhibitors alone did not affect neuronal excitability. The results suggest an important role for the novel mGluR5- IP(3)-ROS-ERK/PKA signaling pathway in amygdala pain mechanisms.

Indexed as

AmygdalaAnalysis of VarianceAnimalsAntioxidantsBenzoatesCyclic AMP-Dependent Protein KinasesCyclic N-OxidesEnzyme InhibitorsExcitatory Amino Acid AntagonistsExtracellular Signal-Regulated MAP KinasesGlycineInositol 1,4,5-TrisphosphateMacrocyclic CompoundsMitochondriaNeuronsNG-Nitroarginine Methyl Ester3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridinealpha-methyl-4-carboxyphenylglycineAntioxidantsBenzoatesCyclic AMP-Dependent Protein KinasesCyclic N-OxidesEnzyme InhibitorsExcitatory Amino Acid AntagonistsExtracellular Signal-Regulated MAP KinasesGlycineInositol 1,4,5-TrisphosphateMacrocyclic CompoundsNG-Nitroarginine Methyl EsterOxazolesPyridinesReactive Oxygen SpeciesReceptor, Metabotropic Glutamate 5Receptors, Metabotropic GlutamateSpin LabelsSuperoxidestempolThiazolesxestospongin C

Identifiers

PMID21248136
PMCPMC3073477
OpenAlexW2060053691

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.